INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 285 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,733,902 | -5.6% | 186,867 | +14.8% | 0.01% | 0.0% |
| Q2 2023 | $10,306,787 | +1448.3% | 162,773 | +1224.1% | 0.01% | +700.0% |
| Q1 2023 | $665,666 | -21.6% | 12,293 | -23.4% | 0.00% | 0.0% |
| Q4 2022 | $849,577 | +5.5% | 16,054 | -7.2% | 0.00% | 0.0% |
| Q3 2022 | $805,000 | +7.2% | 17,305 | +31.6% | 0.00% | 0.0% |
| Q2 2022 | $751,000 | -95.1% | 13,151 | -98.7% | 0.00% | -94.1% |
| Q4 2016 | $15,458,000 | -34.8% | 1,024,366 | -34.1% | 0.02% | -34.6% |
| Q3 2016 | $23,703,000 | -52.3% | 1,555,316 | +21.5% | 0.03% | -52.7% |
| Q2 2016 | $49,674,000 | +39.9% | 1,279,597 | +0.2% | 0.06% | +48.6% |
| Q1 2016 | $35,518,000 | -47.5% | 1,277,610 | +1.6% | 0.04% | -43.9% |
| Q4 2015 | $67,660,000 | +320.4% | 1,257,846 | +212.9% | 0.07% | +312.5% |
| Q3 2015 | $16,096,000 | – | 402,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |